Loading stock…

Guardian Pharmacy Services, Inc. (GRDN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Guardian Pharmacy Services, Inc.

GRDNMarket cap $2.58BPrice $40.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Supplies medications and pharmacy management to long-term care facilities, serving seniors who need complex daily prescriptions. Operates through a network of local pharmacies, blending personalized care with the scale needed to serve one of healthcare's fastest-growing, most vulnerable populations.

In Bastion Portfolios?

52W Return+63%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+17%9

Revenue Forecast

Rev CAGR (1y)-0%2

Rev CAGR (3y)+5%4

Rev CAGR (5y)+4%4

Earnings Forecast

EPS Growth Y+1+68%10

EPS Growth Y+2+10%7

EPS Growth Y+3+13%7

Quality

Margins

EBIT Margin6%3

Net Income Margin5%3

Free Cash Flow Margin5%4

Debt

Net Debt/EBITDA-0.410

Efficiency

ROE32%9

ROA17%10

Earnings Stability88

GEAR+AVERAGE52

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)302

P/E Ratio (Forward 3y)252

P/BV10.52

EV Multiples

EV/EBITDA Fwd202

EV/EBIT Fwd263

Yield

Free Cash Flow Yield3.1%5

Dividend Yieldna–

Momentum

Short term

1 month return-4%6

3 month return+1%7

YTD return+35%9

Mid term

Price vs 52wHigh84%6

1 year return+72%10

Long term

3 year return+154%9

5 year return+154%8

Risk Shield

Price Risk

Beta0.57

Volatility40%4

Free Cash Flow

Free Cash Flow Margin5%4

Free Cash Flow Yield3.1%5

Quality

ROCE34%10

Earnings Stability88

Net Debt/EBITDA-0.410

02Growth

Is it actually growing, and how fast?

GRDNGuardian Pharmacy Services

Revenue FY25$1.4B

GROWTH RATING↗

AVERAGE41 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+68%10

EPS growth, FY27E+10%7

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Earnings are set to grow faster than sales (EPS about 13%/yr vs revenue 5%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 41% of companies worldwide.

Revenue grew 17%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Revenue is set to grow 5%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG82 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+1%7

YTD return+35%9

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+72%10

3-year return+154%9

5-year return+154%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +154% over three years and +154% over five, ahead of 80% of the market.

It's up 72% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+1%) and so far this year (+35%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Guardian Pharmacy Services, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GRDNGuardian Pharmacy Services

Revenue FY25$1.4B

GROWTH RATING↗

AVERAGE41 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+68%10

EPS growth, FY27E+10%7

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Earnings are set to grow faster than sales (EPS about 13%/yr vs revenue 5%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 41% of companies worldwide.

Revenue grew 17%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Revenue is set to grow 5%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG82 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+1%7

YTD return+35%9

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+72%10

3-year return+154%9

5-year return+154%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +154% over three years and +154% over five, ahead of 80% of the market.

It's up 72% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+1%) and so far this year (+35%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Guardian Pharmacy Services, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community